SMARTER-CM: The SMARTER Cardiomyopathy Study
Study Details
Study Description
Brief Summary
Cardiomyopathies are diseases of the heart muscle. Known genetic factors may account for some cardiomyopathy cases but there is still much to understand about the genetic and environmental causes and how the disease progresses.
Finding new ways to diagnose and treat cardiomyopathies could improve the health and well-being of patients with these conditions.
This study will collect data from individuals with cardiomyopathy or related heart muscle disease, or with a possible genetic predisposition to cardiomyopathy, and follow them over time to observe the progress of their heart and health. This study will collect DNA, blood samples, and detailed clinical & lifestyle information at the start of the study, and data collected during routine healthcare visits over time.
-
learn what causes cardiomyopathy, and therefore how to treat it
-
understand why cardiomyopathy progresses differently in different people, to improve the ability to recognise who will benefit from different treatments at different times
The investigators will collaborate with other centres internationally to collect a large of group of participants with similar cardiomyopathies, providing power to identify new pathways that cause disease and ways of predicting which participants are at risk of having more severe disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Cardiomyopathies Approximately 1000 participants recruited prospectively from participating sites with a diagnosis of cardiomyopathy Participants will provide biosamples and allow access to medical scans and records for health data collection |
Other: Blood Sample Collection
Blood for DNA and biomarker analysis
|
Outcome Measures
Primary Outcome Measures
- Incidence of genetic variants [5 years]
Rare and common genetic variants in people with cardiomyopathy
- The incidence of major adverse cardiovascular events over 5 years [5 years]
The incidence of major adverse cardiovascular events over 5 years, defined as:- Cardiovascular death Major arrhythmic events (ventricular fibrillation, unstable sustained ventricular tachycardia, appropriate implantable cardioverter-defibrillator delivered shock, and aborted sudden cardiac death) Major heart failure events (heart transplantation, left ventricular assist device implantation, unplanned heart failure hospitalisation)
Eligibility Criteria
Criteria
Inclusion Criteria:
Adults with the capacity to consent Children with parental/guardian consent Male and Female
Meeting the following criteria:
-
Patients with a confirmed diagnosis of cardiomyopathy or related condition
-
Patients with a family member with cardiomyopathy, or a related condition
-
Patients with a genetic variant that may predispose to cardiomyopathy, or a related condition
Exclusion Criteria:
Patients without the capacity to provide informed consent
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Imperial College London
Investigators
- Principal Investigator: James Ware, Imperial College London
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 22IC7783